A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)

Inclusion Criteria: * Signed Informed Consent Form * Age≥18 years * Histologically or cytologically confirmed advanced non-small cell lung cancer * Must have evidence of c-Met dysregulation from the results of molecular pre-screening evaluations * At least one measurable lesion as per RECIST v1.1 * Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 1 * ECOG Performance Status of 0-1. Exclusion Criteria: * Symptomatic central nervous system (CNS) metastases that are neurologically unstable or requiring increasing doses of steroids to control, and patients with any CNS deficits. * Clinically significant, uncontrolled heart diseases Unstable angina History of documented congestive heart failure (New York Heart Association functional classification \> II) Uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) ≥ 160 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 100 mm Hg Arrhythmias * Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1, except for alopecia * Major surgery within 4 weeks prior to starting PLB1001 * Previous anti-cancer and investigational agents within 2 weeks before first dose of PLB1001. If previous treatment is a monoclonal antibody, then the treatment must be discontinued at least 4 weeks before first dose of PLB1001 * Pregnant or nursing women * Involved in other clinical trials \< 2 weeks prior to Day. If previous treatment of clinical trial is a monoclonal antibody, then the treatment must be discontinued at least 4 weeks before first dose of PLB1001.